BALDWIN PARK, Calif.,
July 27, 2021 /PRNewswire/ --
Southern California cord blood
therapeutics company StemCyte Inc. has received reaccreditation by
AABB. Since 2003, StemCyte has continuously held AABB
accreditation, according to Medical Director Lawrence D. Petz, MD. During this recent
accreditation cycle, the company received zero nonconformances.
StemCyte Inc. receives reaccreditation by AABB. Medical Director
Lawrence Petz, MD, confirms zero
nonconformances.
AABB (formerly known as the American Association of Blood Banks)
is a non-profit organization founded in 1947 that is dedicated to
the education, formulation of standards, policy and other facets of
transfusion medicine and emerging biotherapies. To earn AABB
accreditation, facilities must undergo a rigorous onsite assessment
of their quality and operational systems conducted by a highly
trained assessor whose primary aim is to ascertain whether the
facility meets or exceeds the standards established by AABB.
"We are very pleased to have received no nonconformances during
our AABB assessment for reaccreditation," said StemCyte President
and Chairman Jonas Wang, PhD. "The
assessment covered all aspects of cord blood collection,
processing, storage, testing and distribution. Perhaps the proudest
moment was when the assessor complimented StemCyte for our
commitment to ensuring the quality of both our public and
privately banked cord blood units." He added, "This is in large
part due to the constant striving of our team to provide the same
high level of quality and compliance attributed to the public cord
blood units collected for the California state cord blood program. To the
extent possible, we apply these same quality standards equally for
the benefit of our family bank clients. Since StemCyte's clinical
transplant experience is substantial with over 2,200 cord blood
transplants to date, our private clients may rest assured that our
transplant and clinical trial experience is reflected in the
quality of our privately banked units as well."
"Even though privately banked units do not typically require the
same stringent screening, processing, and testing requirements as
public units, StemCyte has aimed higher to better ensure that our
clients get the quality, safety, and future usability of their
units for transplant or trials," said StemCyte CEO Tong-Young Lee,
PhD.
StemCyte is a privately-owned cord blood regenerative
therapeutics company established in 1997. In its mission statement,
the company emphasizes its dedication to helping the world's
physicians save more lives by providing high quality, safe and
effective stem cell products to all patients in need. With this
most recent successful reaccreditation by AABB, StemCyte is well
positioned to continue its mission through continuous improvement
efforts, by evolving organically into areas of regenerative
medicine research, and by advancing their ongoing work on clinical
trials for spinal cord injury, acute stroke, and COVID-19.
CONTACT:
StemCyte Inc.
publicbank@StemCyte.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/southern-california-stemcyte-inc-receives-aabb-reaccreditation-301342314.html
SOURCE StemCyte